HLB "Riboceranib and Radiation Combination Confirmed Effective for Early Lung Cancer"

HLB announced on the 17th that the anticancer new drug 'Rivoceranib' demonstrated efficacy in a clinical trial combining Rivoceranib with radiation therapy for patients with early-stage metastatic lung cancer.

HLB CI. [Photo by HLB]

This clinical trial was conducted at Haikou University Hospital in China, involving 64 patients with early-stage cancer antigen (CEA) and vascular endothelial growth factor (VEGF)-expressing oligometastatic non-small cell lung cancer who had previously undergone tumor resection surgery. Oligometastatic cancer refers to an early stage of cancer metastasis where partial metastasis occurs in five or fewer organs.

Among the 64 patients, 32 in the experimental group received Rivoceranib (Chinese name Apatinib) combined with radiation therapy, while the other 32 in the control group were treated with radiation therapy (SBRT) alone. According to the company, the trial results showed that the experimental group exhibited drug efficacy with 7 complete responses (CR) and an objective response rate (ORR) of 90.63%, whereas the control group showed 6 CRs and an ORR of 65.62%.

The median progression-free survival (mPFS) was 15.6 months and 13.4 months, respectively. The median overall survival (mOS) was 20 months in the control group, while more than half of the patients in the experimental group survived beyond this period, so mOS was not reached. There were no significant differences in adverse effects between the two groups.

The researchers evaluated that "through this clinical trial, it was confirmed that combining Rivoceranib with radiation therapy significantly improved treatment efficacy in patients with oligometastatic non-small cell lung cancer, markedly reduced cancer biomarkers, and greatly extended patients' overall survival."

Rivoceranib has a mechanism of action that blocks VEGF, an angiogenesis factor, from binding to receptors on the surface of vascular endothelial cells. HLB explained that it has demonstrated significant anticancer effects in various cancer types including liver cancer, lung cancer, stomach cancer, and salivary gland cancer.

HLB, which holds the global rights to Rivoceranib, has completed a global Phase 3 trial as a first-line treatment for liver cancer and plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) next month.

This content was produced with the assistance of AI translation services.